Psychedelic Health

Are psychedelic “trips” essential for healing, or just a side effect?

A recent article by Albert Garcia-Romeu, PhD explores how substances like ketamine, M**A, psilocybin, and L*D shape perception, emotion, and self-awareness. While these experiences can predict some therapeutic benefits biology may play an even bigger role.

From boosting brain plasticity to reducing inflammation, scientists are uncovering pathways to healing that may not require hallucinations at all.

With new compounds in development, the future of psychedelic therapy may look very different.

👉 Read more:

How Important is the "Trip" in Psychedelics-assisted Psychotherapy? A new article published in Nature by Dr. Albert Garcia-Romeu, Associate Professor at Johns Hopkins University, looks at whether the mind-bending, hallucinogenic experiences from psychedelics truly underpin their mental health benefits. Psychedelic substances such as psilocybin and L*D are known for....

Mychedelica launches to revolutionise psychedelic medicine A new company specialising in psychedelic medicine - mychedelica - is offering a comprehensive suite of services to support the advancement of this transformative field.

The first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.

Find out more. 👇

First psilocybin trial for bipolar depression shows promising results The first-ever psilocybin trial for treatment-resistant bipolar type II disorder has shown 80% of participants meeting remission criteria 12 weeks after treatment.